R-ESHAP regimen: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[etoposide]], [[methylprednisolone|(Solumedrol, high-dose)]], [[cytarabine|cytarabine (Ara-C)]], and [[cisplatin|cisplatin (Platinol)]] used to treat | {{PAGENAME}} refers to a salvage regimen consisting of [[rituximab]], [[etoposide]], [[methylprednisolone|(Solumedrol, high-dose)]], [[cytarabine|cytarabine (Ara-C)]], and [[cisplatin|cisplatin (Platinol)]] used to treat refractory [[diffuse large B-cell lymphoma]].<ref name="pmid19336744">{{cite journal| author=Martín A, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea| title=R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome. | journal=Haematologica | year= 2009 | volume= 94 | issue= 5 | pages= 744 | pmid=19336744 | doi=10.3324/haematol.2009.006452 | pmc=PMC2675691 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19336744 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 20: | Line 20: | ||
==Indications== | ==Indications== | ||
* [[Diffuse large B-cell lymphoma]]<ref name="pmid19336744">{{cite journal| author=Martín A, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea| title=R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome. | journal=Haematologica | year= 2009 | volume= 94 | issue= 5 | pages= 744 | pmid=19336744 | doi=10.3324/haematol.2009.006452 | pmc=PMC2675691 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19336744 }} </ref> | |||
==References== | ==References== | ||
Revision as of 18:15, 31 March 2015
|
WikiDoc Resources for R-ESHAP regimen |
|
Articles |
|---|
|
Most recent articles on R-ESHAP regimen Most cited articles on R-ESHAP regimen |
|
Media |
|
Powerpoint slides on R-ESHAP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-ESHAP regimen at Clinical Trials.gov Trial results on R-ESHAP regimen Clinical Trials on R-ESHAP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-ESHAP regimen NICE Guidance on R-ESHAP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-ESHAP regimen Discussion groups on R-ESHAP regimen Patient Handouts on R-ESHAP regimen Directions to Hospitals Treating R-ESHAP regimen Risk calculators and risk factors for R-ESHAP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-ESHAP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Etoposide, Solumedrol (Methylprednisolone) High-dose Ara-C (Cytarabine), Platinol (Cisplatin)
Overview
R-ESHAP regimen refers to a salvage regimen consisting of rituximab, etoposide, (Solumedrol, high-dose), cytarabine (Ara-C), and cisplatin (Platinol) used to treat refractory diffuse large B-cell lymphoma.[1]
Regimen
RRituximab
EEtoposide
SHMethypredisolone (Solumedrol), High-dose
ACytarabine (Ara C)
PCisplatin (Platinum)
Indications
References
- ↑ 1.0 1.1 Martín A, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (2009). "R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome". Haematologica. 94 (5): 744. doi:10.3324/haematol.2009.006452. PMC 2675691. PMID 19336744.